Long-term study of RAP-219 in adults with focal epilepsy
Tests the investigational drug RAP-219 for long-term safety in adults with hard-to-control focal seizures.
Plain-language title generated from the registry record
Registry title: A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
Key facts
- Where
- Boise, Cleveland, Houston, Nashville, New York, Philadelphia, and Rochester, United StatesSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07219407, who can take part
Where in United States
- Consultants in Epilepsy and Neurology PLLCBoise, United StatesTaking people
- Cleveland Clinic FoundationCleveland, United StatesTaking people
- Baylor College of MedicineHouston, United StatesTaking people
- Vanderbilt University Medical CenterNashville, United StatesTaking people
- NYU Langone Comprehensive Epilepsy CenterNew York, United StatesTaking people
- University of Pennsylvania - Department of NeurologyPhiladelphia, United StatesTaking people
- Mayo ClinicRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rapport Therapeutics Inc.
- Trial code
- NCT07219407
- Record updated
- 23 January 2026
- Original description
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.Read full original descriptionShow less
An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
Inclusion: Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator; Diagnosis of refractory focal epilepsy; Stable RNS(c) system settings; A demonstrated history of compliance with RNS(c) system data interrogation and upload; Good overall health other than focal epilepsy, per Investigator; BMI ≥ 18 kg/m\^2 and ≤ 45 kg/m\^2; Willing and able to adhere to all aspects of the protocol.
Exclusion: Known of hypersensitivity to RAP-219; Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator; Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods.